Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ketoconazole

FDA-approved product (tablet, oral), marketed as Extina, Ketoconazole, Ketozole and 3 more.

Registered studies
50+
Lab records
1
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Ketoconazole
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Adrenal gland disease
  • Blastomycosis
  • Cushing syndrome
  • Seborrheic dermatitis
  • Tinea
  • Tinea pedis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Imidazole and triazole derivatives; Imidazole derivatives; Anticorticosteroids
FDA pharmacologic class
Azole Antifungal FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC D01AC08; WHO ATC G01AF11; WHO ATC J02AB02; FDA class Azole Antifungal

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA63.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli33.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis81.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • M. tuberculosis: measured active in 1 of 1 lab record
Open Ketoconazole in ChEMBL Registered studies below
Show the 1 laboratory record, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-5.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ketoconazole with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Drug Interaction Study to Investigate Co-administration of GW642444M With Ketoconazole

    NCT00866515 · start 2008-12-22

    Registered record
    Registry ID
    NCT00866515
    Conditions
    Pulmonary Disease, Chronic Obstructive
    Interventions
    Ketoconazole + GW642444M; Placebo + GW642444M
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-12-22
    Completion
    2009-03-27
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Disease, Chronic Obstructive
    InterventionKetoconazole + GW642444M; Placebo + GW642444M
    PhasePhase 1
    Registry statusCompleted

  • Safety and Efficacy of Ketoconazole 2% Foam in the Treatment of Pityrosporum Folliculitis

    NCT00824863 · start 2008-12

    Registered record
    Registry ID
    NCT00824863
    Conditions
    Pityrosporum Folliculitis
    Interventions
    ketoconazole 2% foam
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-12
    Completion
    2010-06
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPityrosporum Folliculitis
    Interventionketoconazole 2% foam
    PhasePhase 4
    Registry statusCompleted

  • A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ABT-333

    NCT00768690 · start 2008-10

    Registered record
    Registry ID
    NCT00768690
    Conditions
    HCV Infection
    Interventions
    ABT-333; ketoconazole; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-10
    Completion
    Not recorded
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHCV Infection
    InterventionABT-333; ketoconazole; placebo
    PhasePhase 1
    Registry statusCompleted

  • To Evaluate The Effect Of Ketoconazole, Ritonavir and Erythromycin on the Safety and Pharmacokinetics of Avanafil

    NCT00770042 · start 2008-10

    Registered record
    Registry ID
    NCT00770042
    Conditions
    Erectile Dysfunction
    Interventions
    Ritonavir; Ketoconazole; Erythomycin; Avanafil; Avanafil; Avanafil
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-10
    Completion
    2008-12
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErectile Dysfunction
    InterventionRitonavir; Ketoconazole; Erythomycin; Avanafil +2 more
    PhasePhase 1
    Registry statusCompleted

  • Investigation of Antipsoriatic Effects of UVB-induced Synthesis of 1alpha, 25-Dihydroxyvitamin D3 (1alpha, 25(OH)2D3, Calcitriol)in Keratinocytes of Psoriatic Skin, Using Cytochrom-P(CYP)Inhibitor Ketokonazol

    NCT00678756 · start 2008-03

    Registered record
    Registry ID
    NCT00678756
    Conditions
    Psoriasis Vulgaris
    Interventions
    Ketokonazol 2% cream; UVB-radiation 311nm
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2008-03
    Completion
    2009-12
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis Vulgaris
    InterventionKetokonazol 2% cream; UVB-radiation 311nm
    PhasePhase 2
    Registry statusUnknown

  • Study to Evaluate the Effect of Rifampicin, Ketoconazole, and Omeprazole on the Pharmacokinetics of Sativex

    NCT01323465 · start 2008-02

    Registered record
    Registry ID
    NCT01323465
    Conditions
    Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4; Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Potent Inhibitor of CYP3A4; Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a CYP2C19 Inhibitor
    Interventions
    Sativex and rifampicin; Sativex and rifampicin; Sativex and ketoconazole; Sativex and ketoconazole; Sativex and omeprazole; Sativex and omeprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-02
    Completion
    2008-03
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEvaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4; Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Potent Inhibitor of CYP3A4; Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a CYP2C19 Inhibitor
    InterventionSativex and rifampicin; Sativex and rifampicin; Sativex and ketoconazole; Sativex and ketoconazole +2 more
    PhasePhase 1
    Registry statusCompleted

  • Ketoconazole, Dexamethasone, and Hydrocortisone in Treating Patients With Prostate Cancer That Did Not Respond to Androgen-Deprivation Therapy

    NCT00559481 · start 2007-10

    Registered record
    Registry ID
    NCT00559481
    Conditions
    Prostate Cancer
    Interventions
    dexamethasone; ketoconazole; therapeutic hydrocortisone; pharmacological study
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2007-10
    Completion
    Not recorded
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Interventiondexamethasone; ketoconazole; therapeutic hydrocortisone; pharmacological study
    PhaseNot applicable
    Registry statusWithdrawn

  • Effect of Ketoconazole Inhibition of CYP3A on Urinary Excretion of Docetaxel

    NCT00697437 · start 2006-10

    Registered record
    Registry ID
    NCT00697437
    Conditions
    Solid Tumors
    Interventions
    Docetaxel; Ketoconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-10
    Completion
    2013-10
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumors
    InterventionDocetaxel; Ketoconazole
    PhasePhase 2
    Registry statusCompleted

  • A Randomized, Multiple Dose, Double Blind, 5-way Crossover Study of the Electrocardiographic (ECG) Effects of Bilastine

    NCT00419783 · start 2006-08

    Registered record
    Registry ID
    NCT00419783
    Conditions
    Healthy
    Interventions
    bilastine; Bilastine; Bilastine & Ketoconazole; Moxifloxacin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-08
    Completion
    2006-12
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventionbilastine; Bilastine; Bilastine & Ketoconazole; Moxifloxacin +1 more
    PhasePhase 1
    Registry statusCompleted

  • Study of Dasatinib in Patients With Advanced Solid Tumors

    NCT00162214 · start 2005-08

    Registered record
    Registry ID
    NCT00162214
    Conditions
    Tumors
    Interventions
    Dasatinib + Ketoconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2005-08
    Completion
    2007-03
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTumors
    InterventionDasatinib + Ketoconazole
    PhasePhase 1
    Registry statusTerminated

  • Selenium Sulfide, Ketoconazole and Ciclopirox Shampoo as Additional Treatments for Tinea Capitis (Scalp Ringworm)

    NCT00127868 · start 2005-03

    Registered record
    Registry ID
    NCT00127868
    Conditions
    Tinea Capitis
    Interventions
    oral griseofulvin, selenium sulfide shampoo 1%, ciclopirox shampoo , ketoconazole shampoo 2%, baby shampoo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2005-03
    Completion
    2008-04
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTinea Capitis
    Interventionoral griseofulvin, selenium sulfide shampoo 1%, ciclopirox shampoo , ketoconazole shampoo 2%, baby shampoo
    PhaseNot applicable
    Registry statusCompleted

  • Calcitriol, Ketoconazole, and Dexamethasone in Treating Patients With Metastatic or Unresectable Solid Tumors

    NCT00238225 · start 2004-11

    Registered record
    Registry ID
    NCT00238225
    Conditions
    Unspecified Adult Solid Tumor, Protocol Specific
    Interventions
    calcitriol; dexamethasone; ketoconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2004-11
    Completion
    Not recorded
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUnspecified Adult Solid Tumor, Protocol Specific
    Interventioncalcitriol; dexamethasone; ketoconazole
    PhasePhase 1
    Registry statusCompleted

  • Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation

    NCT00675714 · start 2004-01

    Registered record
    Registry ID
    NCT00675714
    Conditions
    Burns
    Interventions
    Stable Isotope Infusion Study; Collection of blood and tissues; Radiology testing: Dual-energy X-ray absorptiometry (DEXA), ultrasound, MRI; Humatrope; Ketoconazole; Oxandrolone; Propranolol; Oxandrolone and propranolol combined; Humatrope and propranolol combined; Placebo; Exercise--Hospital supervised intensive exercise program; Home exercise program
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Terminated
    Start
    2004-01
    Completion
    2019-07-15
    Enrolment
    1,126

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBurns
    InterventionStable Isotope Infusion Study; Collection of blood and tissues; Radiology testing: Dual-energy X-ray absorptiometry (DEXA), ultrasound, MRI; Humatrope +8 more
    PhasePhase 2 / Phase 3
    Registry statusTerminated

  • Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer

    NCT00024167 · start 2002-04

    Registered record
    Registry ID
    NCT00024167
    Conditions
    Prostate Cancer
    Interventions
    Docetaxel; Doxorubicin hydrochloride; Estramustine phosphate sodium; Ketoconazole; Prednisone; Vinblastine; Strontium chloride Sr 89; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2002-04
    Completion
    Not recorded
    Enrolment
    265

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionDocetaxel; Doxorubicin hydrochloride; Estramustine phosphate sodium; Ketoconazole +4 more
    PhasePhase 3
    Registry statusTerminated

  • Ketoconazole Plus Docetaxel to Treat Prostate Cancer

    NCT00032825 · start 2002-03-19

    Registered record
    Registry ID
    NCT00032825
    Conditions
    Prostatic Neoplasms
    Interventions
    Ketaconazole; Docetaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2002-03-19
    Completion
    2011-06-13
    Enrolment
    674

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Neoplasms
    InterventionKetaconazole; Docetaxel
    PhasePhase 1
    Registry statusCompleted